As filed with the Securities and Exchange Commission on March 25, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Inozyme Pharma, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware |
| 38-4024528 |
(State or Other Jurisdiction of Incorporation or Organization) |
| (I.R.S. Employer Identification No.) |
|
| |
321 Summer Street Suite 400 Boston, Massachusetts |
| 02210 |
(Address of Principal Executive Offices) |
| (Zip Code) |
2020 Stock Incentive Plan
2020 Employee Stock Purchase Plan
(Full Title of the Plan)
Axel Bolte
President and Chief Executive Officer
321 Summer Street
Suite 400
Boston, Massachusetts 02210
(Name and Address of Agent For Service)
(857) 330-4340
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
| ☐ |
| Accelerated filer |
| ☐ |
|
|
|
| |||
Non-accelerated filer |
| ☒ |
| Smaller reporting company |
| ☒ |
|
|
| ||||
|
| Emerging growth company |
| ☒ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
| ||||||||
Title of securities to be registered |
| Amount to be registered(1) |
| Proposed maximum offering price per share |
| Proposed maximum aggregate offering price |
| Amount of registration fee |
Common Stock, par value $0.0001 per share |
| 1,169,247(2) |
| $19.16(3) |
| $22,402,773(3) |
| $2,444.15 |
| ||||||||
| ||||||||
(1) | In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
(2) | Consists of an additional (i) 935,398 shares issuable under the 2020 Stock Incentive Plan and (ii) 233,849 shares issuable under the 2020 Employee Stock Purchase Plan. |
(3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low sale prices of the Registrant’s Common Stock as reported on the Nasdaq Global Select Market on March 23, 2021. |
STATEMENT OF INCORPORATION BY REFERENCE
This Registration Statement on Form S-8, relating to the 2020 Stock Incentive Plan of Inozyme Pharma, Inc. (the “Registrant”) and the 2020 Employee Stock Purchase Plan of the Registrant, is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the 2020 Stock Incentive Plan and the 2020 Employee Stock Purchase Plan has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8, File No. 333-240146, filed with the Securities and Exchange Commission on July 28, 2020 by the Registrant, relating to the Registrant’s Amended and Restated 2017 Equity Incentive Plan, as amended, 2020 Stock Incentive Plan and 2020 Employee Stock Purchase Plan, except for Item 8, Exhibits.
Item 8. | Exhibits |
|
|
|
Number |
| Description |
|
| |
4.1 |
| |
4.2 |
| |
|
| |
5.1* |
| Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant |
|
| |
23.1* |
| Consent of Ernst & Young LLP, independent registered public accounting firm |
|
| |
23.2* |
| Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1) |
|
| |
24.1* |
| Power of Attorney (included on the signature pages of this registration statement) |
|
| |
99.1 |
| |
|
| |
99.2 |
| |
* | Filed herewith |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 25th day of March, 2021.
|
|
|
INOZYME PHARMA, INC. | ||
|
| |
By: |
| /s/ Axel Bolte |
|
| Axel Bolte |
|
| President and Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Inozyme Pharma, Inc., hereby severally constitute and appoint Axel Bolte and Stephen Basso, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Inozyme Pharma, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
| Title |
| Date |
|
|
| ||
/s/ Axel Bolte Axel Bolte |
| President and Chief Executive Officer, Director |
| March 25, 2021 |
|
|
| ||
/s/ Stephen Basso Stephen Basso |
| Senior Vice President, Finance (Principal Financial and Accounting Officer) |
| March 25, 2021 |
|
|
| ||
/s/ Douglas Treco Douglas Treco |
| Chairman |
| March 25, 2021 |
|
|
| ||
/s/ Sarah Bhagat Sarah Bhagat |
| Director |
| March 25, 2021 |
|
|
| ||
/s/ Reinaldo Diaz Reinaldo Diaz |
| Director |
| March 25, 2021 |
|
|
| ||
/s/ Martin Edwards Martin Edwards |
| Director |
| March 25, 2021 |
|
|
| ||
/s/ Robert Hopfner Robert Hopfner |
| Director |
| March 25, 2021 |
|
| |||
/s/ Edward Mathers Edward Mathers
|
| Director |
| March 25, 2021 |
/s/ Lynne Sullivan Lynne Sullivan |
| Director |
| March 25, 2021 |
